Interestingly, recent in vitro experiments showed that CDK12 drove trastuzumab resistance and treatment with a CDK12 inhibitor enhanced the sensitivity to anti‐HER2 therapy through the PI3K/Akt and Wnt pathways in breast cancer.24, 25. Here, ERBB2 is linked to breast carcinoma.